Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroPaceNPCE -2.99%69 Days Sales Outstanding is 59.40 as of Jun. 2026, which is 2% above its 10-year median of 58.43. GuruFocus rates NPCE with a GF Score™ of 69/100 and a GF Value™ of $12.60 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 810 Medical Devices & Instruments companies, NeuroPace ranks better than 65.31% on this metric.
NeuroPace's average Accounts Receivable for the
three
months ended in Jun. 2026 was $14.86 Mil. NeuroPace's Revenue for the
three
months ended in Jun. 2026 was $22.83 Mil.
Hence, NeuroPace's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 59.40.
The historical rank and industry rank for NeuroPace's Days Sales Outstanding or its related term are showing as below:
NPCE'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.25 Med: 58.43 Max: 63.94
Current: 53.84
During the past 7 years, NeuroPace's highest Days Sales Outstanding was 63.94. The lowest was 50.25. And the median was 58.43.
NPCE's Days Sales Outstanding is ranked better than 65.31% of 810
companies
in the Medical Devices & Instruments industry
Industry Median: 65.25
vs NPCE: 53.84
NeuroPace's Days Sales Outstanding
declined
from Jun. 2025 (67.82) to Jun. 2026 (59.40).
NeuroPace (NAS:NPCE) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
NeuroPace Days Sales Outstanding Related Terms
NeuroPace Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for NeuroPace's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NPCE vs SENS, CLPT, SGHT: Days Sales Outstanding Comparison
For the Medical Devices subindustry, NeuroPace's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where NeuroPace's Days Sales Outstanding falls into.
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroPace (NPCE) has a Days Sales Outstanding of 59.40 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on NeuroPace and its competitors. This is near median its historical median of 58.43. Over the past decade, NeuroPace's Days Sales Outstanding has ranged from 50.25 to 63.94. According to the industry distribution chart, NeuroPace ranks #281 out of 810 companies in the Medical Devices & Instruments industry, placing it in the top 34.7%.
Is NeuroPace's Days Sales Outstanding too high?
NeuroPace's current Days Sales Outstanding of 59.40 is near median its 10-year median of 58.43. Over the past 10 years, this metric has ranged from a low of 50.25 to a high of 63.94. The Medical Devices & Instruments industry median Days Sales Outstanding is 65.25. NeuroPace's value of 59.40 is 9% below this industry median. Based on the distribution chart, NeuroPace ranks #281 out of 810 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NeuroPace has a GF Score™ of 69/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's Days Sales Outstanding compare to SENS and CLPT?
According to the Medical Devices & Instruments industry distribution chart, NeuroPace ranks #281 out of 810 companies for Days Sales Outstanding. This puts NeuroPace in the upper half of its industry. The industry median Days Sales Outstanding is 65.25. NeuroPace's value of 59.40 is 9% below this benchmark. Historically, NeuroPace's own Days Sales Outstanding has ranged from 50.25 to 63.94 over the past decade. While the company's 10-year median is 58.43 vs. the industry median of 65.25, NeuroPace has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 65.25, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroPace's current Days Sales Outstanding of 59.40 is 9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on NeuroPace and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 65.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroPace's current Days Sales Outstanding is 59.40, which is near median its own 10-year median of 58.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Modestly Overvalued. The stock's GF Value™ is $12.60, compared to a current price of $14.71 — trading 16.7% above its estimated fair value. The current Days Sales Outstanding is 59.40, which is near median its 10-year median of 58.43 and 9% below the Medical Devices & Instruments industry median of 65.25. NeuroPace's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For NeuroPace (NPCE), the current Days Sales Outstanding is 59.40 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $14.71 is trading 16.7% above its estimated GF Value™ of $12.60.
GuruFocus considers NeuroPace to be Modestly Overvalued.
Key valuation signals for NPCE:
Days Sales Outstanding: 59.40 (near median its 10-year median of 58.43)
GF Value™: $12.60 vs. price of $14.71 (16.7% above fair value)
Industry Position: 9% below the Medical Devices & Instruments median (#281 of 810)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
69GF Score
Get the complete analysis for NPCE
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 
